meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
avelumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
olaparib
rucaparib
target therapy
multikinase inhibitor
nintedanib
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
olaparib
title
Standard of Care (SoC)
title
SOLO 3, 2020 NCT02282020 ovarian cancer (OC) 178/88
SOLO2/ENGOT-Ov21, 2018 NCT01874353 ovarian cancer (OC) 196/99
Ledermann, 2012 NCT00753545 ovarian cancer (OC) 136/129
PAOLA-1/ENGOT-ov25, 2019 NCT02477644 ovarian cancer (OC) 537/269
SOLO 1, 2018 NCT01844986 ovarian cancer (OC) 260/131
Pathology:
ovarian cancer (OC);
ovarian cancer (OC)
SOLO 3, 2020
SOLO2/ENGOT-Ov21, 2018
Ledermann, 2012
PAOLA-1/ENGOT-ov25, 2019
SOLO 1, 2018
olaparib
5
T1
T1
T1
T1
T1
Standard of Care (SoC)
0
T0
T0
T0
T0
T0